FAGR Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort; and Cleoderm, a topical cream used for the compounding of personalized dermatological treatments. It also offers education and professional development of prescribers, hospitals, and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Fagron (EBR: FAGR)
›
Fagron (EBR: FAGR) is listed on Euronext Brussels, where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 4,880 employees.
The shares were at 24.40 EUR on 19 November 2026, up 19.9% over 52 weeks. Its 52-week range is 20.00 EUR to 25.30 EUR: the price is 3.6% below the high and 22.0% above the low.
At a market capitalisation of 1.79B EUR, it trades at 19.5 times trailing earnings and 14.9 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 21% for FAGR. It pays a dividend yielding 1.63% (it pays out 32% of its earnings), against a median of 1.90% among the dividend payers in that peer group.
Fagron reports return on equity of 16.5%, an operating margin of 14.3% and revenue up 16.0% year over year.
Its debt exceeds its cash by 506.44M EUR, a debt-to-equity ratio of 0.85. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 29.00 EUR is 18.9% above the current price. The next earnings report is expected on 11 February 2027.